GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hanall Biopharma Co Ltd (XKRX:009420) » Definitions » ROE % Adjusted to Book Value

Hanall Biopharma Co (XKRX:009420) ROE % Adjusted to Book Value : -0.50% (As of Dec. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Hanall Biopharma Co ROE % Adjusted to Book Value?

Hanall Biopharma Co's ROE % for the quarter that ended in Dec. 2023 was -5.97%. Hanall Biopharma Co's PB Ratio for the quarter that ended in Dec. 2023 was 12.06. Hanall Biopharma Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -0.50%.


Hanall Biopharma Co ROE % Adjusted to Book Value Historical Data

The historical data trend for Hanall Biopharma Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hanall Biopharma Co ROE % Adjusted to Book Value Chart

Hanall Biopharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 1.16 0.78 0.03 0.16

Hanall Biopharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.53 2.87 0.08 -0.50

Competitive Comparison of Hanall Biopharma Co's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Hanall Biopharma Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hanall Biopharma Co's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hanall Biopharma Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Hanall Biopharma Co's ROE % Adjusted to Book Value falls into.



Hanall Biopharma Co ROE % Adjusted to Book Value Calculation

Hanall Biopharma Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=1.98% / 12.06
=0.16%

Hanall Biopharma Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-5.97% / 12.06
=-0.50%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hanall Biopharma Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Hanall Biopharma Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Hanall Biopharma Co (XKRX:009420) Business Description

Traded in Other Exchanges
N/A
Address
12 Bongeunsa-ro 114-gil, Daewoong Building, 3rd Floor, Gangnam-gu, Seoul, KOR
Hanall Biopharma Co Ltd is a part of the healthcare sector. It is one of Korea's leading pharmaceutical companies and is focused on drug delivery, biotherapeutics, and new small molecule discovery. The company's scope comprises of ophthalmology, immunology, cardiovascular treatment and dermatology.

Hanall Biopharma Co (XKRX:009420) Headlines

No Headlines